中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (on line): 1-12.

• •    下一篇

Recent developments of neuroprotective agents for degenerative retinal disorders

  

  • 出版日期:2022-01-01 发布日期:2021-11-25

Recent developments of neuroprotective agents for degenerative retinal disorders

Kepeng Ou1, 2, #, §, Youjian Li1, 2, #, Ling Liu3, Hua Li3, Katherine Cox2, Jiahui Wu2, 4, *, §, Jian Liu2, §, Andrew D. Dick2, 5, 6, §   

  1. 1College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts and Sciences, Chongqing, China; 2Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; 3Department of Ophthalmology, Yongchuan Hospital, Chongqing Medical University, Chongqing, China; 4Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China; 5Institute of Ophthalmology, University College London, London, UK; 6National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, UK
  • Online:2022-01-01 Published:2021-11-25
  • Contact: Jiahui Wu, Jiahui.Wu@bristol.ac.uk.

Abstract: Retinal degeneration is a debilitating ocular complication characterized by the progressive loss of photoreceptors and other retinal neurons, which are caused by a group of retinal diseases affecting various age groups, and increasingly prevalent in the elderly. Age-related macular degeneration, diabetic retinopathy and glaucoma are among the most common complex degenerative retinal disorders, posing significant public health problems worldwide largely due to the ageing society and the lack of effective therapeutics. Whilst pathoetiologies vary, if left untreated, loss of retinal neurons can result in an acquired degeneration and ultimately severe visual impairment. Irrespective of underlined etiology, loss of neurons and supporting cells including retinal pigment epithelium, microvascular endothelium, and glia, converges as the common endpoint of retinal degeneration and therefore discovery or repurposing of therapies to protect retinal neurons directly or indirectly are under intensive investigation. This review overviews recent developments of potential neuroprotectants including neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers and antioxidants either still experimentally or in clinical trials. Effective treatments that possess direct or indirect neuroprotective properties would significantly lift the burden of visual handicap.

Key words: antioxidants, autophagy enhancers, complement inhibitors, exosomes, neuropeptides, neuroprotective agents, retinal degeneration, senolytics